Usefulness of the top-scoring pairs of genes for prediction of prostate cancer progression.
Prediction of cancer progression after radical prostatectomy is one of the most challenging problems in the management of prostate cancer. Gene-expression profiling is widely used to identify genes associated with such progression. Usually candidate genes are identified according to a gene-by-gene comparison of expression. Recent reports suggested that relative expression of a gene pair more efficiently predicts cancer progression than single-gene analysis does. The top-scoring pair (TSP) algorithm classifies phenotypes according to the relative expression of a pair of genes. We applied the TSP approach to predict, which patients would experience systemic tumor progression after radical prostatectomy. Relative expression of TPD52L2/SQLE and CEACAM1/BRCA1 gene pairs identified those patients with more than 99% specificity but relatively low sensitivity (approximately 10%). These two gene pairs were validated in three independent data sets. In addition, combining two pairs of genes improved sensitivity without compromising specificity. Functional annotation of the TSP genes showed that they cluster by a limited number of biological functions and pathways, suggesting that relatively lower expression of genes from specific pathways can predict cancer progression. In conclusion, comparative analysis of the expression of two genes may be a simple and effective classifier for prediction of prostate cancer progression. In summary, the TSP approach can be used to identify patients whose prostate cancer will progress after they undergo radical prostatectomy. Two gene pairs can predict which men would experience progression to the metastatic form of the disease. However, because our analysis was based on a relatively small number of genes, a larger study will be needed to identify the best predictors of disease outcome overall.
Zhao
H
H
Department of Genitourinary Medical Oncology, The University of Texas MD, Anderson Cancer Center, Houston, TX 77030-4009, USA.
Logothetis
C J
CJ
Gorlov
I P
IP
D000465:Algorithms; D014408:Biomarkers, Tumor / Q000235:genetics*; D016022:Case-Control Studies; D019295:Computational Biology; D018450:Disease Progression; D020869:Gene Expression Profiling; D006801:Humans; D008297:Male; D009367:Neoplasm Staging; D020411:Oligonucleotide Array Sequence Analysis; D011379:Prognosis; D011471:Prostatic Neoplasms / Q000175:diagnosis* / Q000235:genetics*; D012680:Sensitivity and Specificity; D015996:Survival Rate
D014408:Biomarkers, Tumor
PLoS One. 2008;3(5):e2318
18846227
Nat Genet. 2007 Jan;39(1):41-51
17173048
Oncogene. 2006 Aug 17;25(36):4965-74
16568082
Cancer Res. 2002 Aug 1;62(15):4499-506
12154061
Toxicol In Vitro. 2006 Mar;20(2):187-210
16289744
Bioinformatics. 2005 Oct 15;21(20):3905-11
16131522
Prostate Cancer Prostatic Dis. 2009;12(4):333-8
19901933
Nature. 2001 Aug 23;412(6849):822-6
11518967
Bioinformatics. 2005 Oct 15;21(20):3896-904
16105897
Clin Cancer Res. 2009 Mar 1;15(5):1558-65
19223505
FASEB J. 2005 Feb;19(2):243-5
15548588
Oncogene. 2007 Mar 22;26(13):1875-84
16983333
Hum Pathol. 2007 Jul;38(7):1081-1091
17442374
FEBS J. 2008 Nov;275(22):5703-13
18959755
BMC Cancer. 2007 Apr 12;7:64
17430594
Prostate. 2010 Feb 15;70(3):270-5
19902474
Cancer Cell. 2002 Mar;1(2):203-9
12086878
Antioxid Redox Signal. 2000 Fall;2(3):585-605
11229370
Cancer Res. 2007 Jun 1;67(11):5117-25
17545589
Nat Genet. 2007 May;39(5):645-9
17401363
Eur J Hum Genet. 2008 Apr;16(4):496-505
18231127
Cell Res. 2002 Dec;12(5-6):311-20
12528889
Mol Carcinog. 2002 Jan;33(1):25-35
11807955
Urol Oncol. 2011 Mar-Apr;29(2):145-9
19269198
Prostate. 2005 May 15;63(3):240-51
15538743
Int J Radiat Oncol Biol Phys. 2009 Apr 1;73(5):1439-45
18963536
Stat Appl Genet Mol Biol. 2004;3:Article19
16646797
J Clin Oncol. 2004 Jul 15;22(14):2790-9
15254046